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Patients pursuing exome sequencing in their quest for diagnosis will most often receive a 
clinically uncertain result. A clinically uncertain result has some level of objective uncertainty as 
viewed by clinicians regarding a patient’s diagnosis. A clinically uncertain result can be a result 
that is negative, with no reportable genetic variants, or that includes one or more genetic variants 
deemed uncertain with regard to the cause of a patient’s condition. Clinically uncertain results 
present challenges to both providers and patients in disclosing and processing ambiguous health 
information. This exploratory study sought insight into the psychological and behavioral impact 
of receiving clinically uncertain results from exome sequencing. Semi-structured phone 
interviews were conducted with 23 adult patients with undiagnosed conditions who have received 
two of the more common types of clinically uncertain results from exome sequencing: either a 
negative result or a result with one or more variants of uncertain significance. Interviews focused 
on the experience of receiving the clinically uncertain result, with emphasis on conceptualization 
of uncertainty and coping. Interviews were transcribed and subjected to thematic analysis, and 
results were analyzed within the context of participants’ diagnostic odysseys. No thematic 
differences were found between the experiences of those who received negative results versus 
those who received one or more variants of uncertain significance. Participants demonstrated a 
variety of conceptualizations of the uncertainty related to their exome sequencing result and 
undiagnosed condition. They were generally acclimated to illness uncertainty due to their lengthy 
and ongoing diagnostic journey, which resulted in realistic expectations about and acceptance of 
their clinically uncertain results. However, participants still hoped that exome sequencing would 
end their diagnostic odyssey, and many remain hopeful that future technological advances will 
provide them with a diagnosis. This residual hope, as well as optimism, were used as coping 
strategies to deal with continued uncertainty. Understanding how patients with undiagnosed 





practices around informed consent and the disclosure of clinically uncertain results through a 
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Exome Sequencing and Clinically Uncertain Results 
The field of medical genetics is advancing rapidly, with greater use of genomic 
approaches such as exome sequencing. Exome sequencing is a genetic test that analyzes the 
exome, or the protein-coding regions of the genome, to detect known disease-causing genetic 
variants that may provide diagnoses for patients. The use of clinical exome sequencing is on the 
rise due to its clinical utility, efficiency, and cost-effectiveness (Yang et al, 2013; Bamshad et al, 
2011). However, this genetic service has been incorporated into clinical practice at a much faster 
rate than that of the medical community’s ability to collect data about the disease-causing 
potential of exonic variants. Therefore, the increased uptake of clinical exome sequencing has 
resulted in an increase in the number of clinically uncertain results. A clinically uncertain result is 
a result that has some level of objective uncertainty viewed by clinicians regarding a patient’s 
diagnosis. A clinically uncertain result can be a result that is negative, with no reportable genetic 
variants, or that includes one or more genetic variants deemed uncertain with regard to the cause 
of a patient’s condition. 
Perhaps the most commonly recognized type of clinically uncertain result is a variant of 
uncertain significance (VUS), or a genetic variant that has not been clearly associated with 
disease and for which pathogenicity is uncertain due to a lack of evidence. Laboratories offering 
clinical exome sequencing may choose to include different VUSs in their test reports (Bertier et 
al, 2016). Laboratories typically limit the VUSs they report to those found in genes that are 
known to cause conditions that are related to the patient’s phenotype. Yet the genes that each 
laboratory chooses to target may vary. Laboratories may also report VUSs that are unrelated to 
the patient’s phenotype, such as those found in the American College of Medical Genetics and 
Genomics (ACMG) list of 59 reportable secondary findings. This ACMG list is a list of genes 





2017). In addition to VUSs, there are various other types of clinically uncertain results that can 
occur from exome sequencing. Among the various types of clinically uncertain results, negative 
results and VUSs appear to be most common (based on personal communication with genetic 
counselors at Johns Hopkins Hospital Genetics Clinics and Kennedy Krieger Institute).  
Exome sequencing has been reported to only provide complete diagnoses to about 25% 
of patients with undiagnosed conditions (the specific percentage is largely dependent upon the 
patient’s clinical presentation) (Berg, 2014; Sawyer et al, 2016; Yang et al, 2013). Therefore, 
undiagnosed patients receive clinically uncertain results from exome sequencing about 75% of 
the time. Because advancements in sequencing technologies have not been matched with 
increased knowledge for genetic variant interpretation, patients with undiagnosed conditions who 
are offered exome sequencing are more often left with uncertainty rather than a diagnosis.  
 
Patients with Undiagnosed Conditions 
Patients with undiagnosed conditions have illnesses that are rare or ambiguous enough to 
elude a specific molecular diagnosis. These patients have often endured a diagnostic odyssey 
characterized by chronic uncertainty. The term diagnostic odyssey has been used to describe the 
onerous and frustrating journey of seeking a diagnosis, one that involves non-diagnostic 
encounters with countless specialists (Basel & McCarrier, 2017). For patients with undiagnosed 
conditions, exome sequencing is usually part of a “last ditch” effort to attain a diagnosis (Sawyer 
et al, 2016). This patient population’s experience with chronic uncertainty related to their illness 
makes them a particularly interesting and relevant population to study regarding responses to 
clinically uncertain results from exome sequencing.  
At the outset of exome sequencing in clinical care, trios of undiagnosed children and their 
parents were typically those receiving the service because trio testing increases diagnostic yield 





diagnosis, while not resolving all uncertainty, can significantly reduce uncertainty through 
providing a label, an explanation of cause, prognostic and treatment information, and avenues for 
social support (Madeo et al, 2012; Rosenthal et al, 2001; Carmichael et al, 2015).  
While several studies have explored perceptions of uncertainty in relationship to genetic 
testing among parents of undiagnosed children (Macnamara et al, 2014; Madeo et al, 2012; 
Rosenthal et al, 2001; Graungaard et al, 2006; Lipinski et al, 2006), adults with undiagnosed 
conditions have only relatively recently been able to take advantage of exome sequencing, and 
their response to uncertainty from exome sequencing is still a relatively new phenomenon that 
requires exploration. Qualitative studies of illness narratives from adults with undiagnosed 
conditions have shown a common theme of chronic uncertainty, but these studies have not 
examined the impact of uncertain genetic test results (Spillmann et al, 2017; Nettleton, 2006; 
Nettleton et al, 2005). One might anticipate certain differences in the ways adult patients with 
undiagnosed conditions experience and perceive genomic uncertainty compared to parents of 




Uncertainty in Illness Theory. In Western society, certainty, predictability, and control 
are the expected and desired outcomes of medicine. Physicians are expected to use scientific 
methods to provide accurate diagnoses and information on effective treatment. When uncertainty 
is the outcome, the medical endeavor is seen as deficient, disrupting an individual’s sense of 
control. As Mishel (1990) explains, uncertainty is “the inability to determine the meaning of 
illness-related events and occurs in situations where the decision maker is unable to assign 





sufficient cues are lacking.” Uncertainty in illness is associated with psychological distress, 
reduced perceived self-efficacy, and an enhanced sense of danger (Mishel, 1990; Neville, 2003). 
The uncertainty in illness theory (UIT) describes how individuals process uncertainty 
related to their illness and how they create meaning around uncertain events. Generally, 
uncertainty is appraised in two ways: positively (as an opportunity) or negatively (as a danger or 
threat). The appraisal outcome dictates coping. If uncertainty is appraised as an opportunity, the 
individual may implement coping strategies to work to maintain the uncertainty. If uncertainty is 
appraised as a danger or threat, the individual may implement coping strategies to reduce the 
uncertainty. Positive psychological adaptation is most likely to occur when coping strategies 
manipulate the uncertainty in the desired direction based on the appraisal (Mishel, 1990). 
Individuals who experience illness involving a short period of uncertainty are often able 
to appraise, cope appropriately based on the appraisal, and adapt to reach a new equilibrium. In 
contrast, individuals who experience long periods of chronic illness with continual uncertainty 
may appraise this uncertainty differently at different time points in their diagnostic odyssey. This 
evolution of appraisals poses challenges to reaching a new equilibrium. Integrating chronic 
uncertainty into one’s sense of self is an arduous journey. Yet if uncertainty is never resolved, 
UIT poses that it may ultimately be evaluated as opportunistic rather than aversive.  However, 
this re-evaluation will change the individual’s world view to now rest on probabilistic and 
conditional thinking, as certainty and predictability are now viewed as unrealistic. An individual 
maintains this new world view by interacting with support resources and healthcare providers 
who share the same world view (Mishel, 1990).     
Conceptualizations of Genomic Uncertainty. Genomic uncertainty is uncertainty derived 
from genomic information. Genomic uncertainty can be conceptualized through Han’s sources of 
uncertainty and Babrow’s forms of uncertainty. Han’s sources of uncertainty characterize the 





of future outcomes that comes with genomic information; ambiguity represents imprecise, 
conflicting, or missing information regarding genomic interpretation; and complexity represents 
genomic information that is challenging to understand. Babrow’s forms of uncertainty describe 
how individuals experience uncertainty from genomic information. First, inherent uncertainty 
arises from the genetic test or condition itself, such as the accuracy and reliability of the specific 
test or the complex genetic cause(s) of an illness. Information uncertainty arises from the 
information that comes from the genetic test. Views on uncertainty describes an individual’s 
perception of the probability of any specific outcome from genetic testing. Structuring of 
information describes how an individual organizes or integrates genomic information into their 
existing beliefs and values. Finally, personal views about knowledge describes how individuals 
interpret genomic information differently based on their preexisting attitudes about the value of 
knowledge (Newson et al, 2016; Han et al, 2011; Babrow, 1998). Han’s and Babrow’s 
characterizations of uncertainty are indeed complementary; Han describes various sources of 
uncertainty from genomic information and Babrow describes different ways in which uncertainty 
from genomic information can be experienced and interpreted. Yet these two characterizations 
also somewhat overlap. For instance, Babrow’s information uncertainty can be characterized by 
Han’s typology. In addition, Han’s probability uncertainty contributes to the experience of 
Babrow’s views on uncertainty.  
Han and colleagues have taken Han’s original conceptualization of genomic uncertainty 
and updated it in A Taxonomy of Medical Uncertainties in Clinical Genome Sequencing (Han et 
al, 2017). This updated taxonomy includes Han’s original sources of genomic uncertainty and his 
additional issues (the matter about which the individual is uncertain), and loci (the party or parties 
who experience the uncertainty) of uncertainty. The taxonomy continues to break down each 
source, issue, and locus into further discrete units to characterize all facets of uncertainty in 





A clinically uncertain result can be characterized by many facets of genomic uncertainty, 
especially in the context of exome sequencing with the goal of providing a diagnosis for a patient 
with an undiagnosed condition. In this context, a clinically uncertain result is marked by the 
dimensions of genomic uncertainty of probability, ambiguity, and complexity. Probability 
uncertainty is derived from the lack of prognostic information that a clinically uncertain result 
provides for the patient. Ambiguity uncertainty can derive from the perceived missing 
information from a negative result, or may derive from the lack of evidence existing to classify a 
VUS. Complexity uncertainty derives from the nature of the result being challenging for some 
patients to understand. In addition to experiencing genomic uncertainty related to these three 
sources, undiagnosed patients responding to clinically uncertain results from exome sequencing 
may describe their experiences in relation to Babrow’s categories.  
Theory of Cognitive Adaptation. Taylor’s theory of cognitive adaptation outlines how 
individuals may successfully adapt to a threatening event. Her theory states that the adaptation 
process occurs in three steps: “a search for meaning in the experience, an attempt to regain 
mastery over the event in particular and over one's life more generally, and an effort to restore 
self-esteem through self-enhancing evaluations” (Taylor, 1983). Meaning-making is achieved 
through an understanding of what caused the threatening event and how it has changed one’s life. 
Regaining mastery centers on beliefs about personal control and requires an understanding of 
how one can manage the threatening event and prevent it from reoccurring. Restoring self-esteem 
is achieved by self-enhancing evaluations, or social comparisons in which the object of 
comparison allows for positive self-perceptions. Taylor posits that the adaptation process occurs 
through the ability to form and maintain illusions, or ways in which to perceive the facts in a 
more positive light (Taylor, 1983). 
The theory of cognitive adaptation may apply to patients with undiagnosed conditions 





or the fact that exome sequencing did not provide a diagnosis, may be a threatening event for the 
patient. The theory of cognitive adaptation theorizes a process in which undiagnosed patients may 
cope and adapt to the threat of uncertainty from clinically uncertain results. 
 
Perceptions of and Responses to Genomic and Illness Uncertainties 
Genomic Uncertainty derived from Exome Sequencing. There are few studies that 
examine interpretations of uncertainty around exome sequencing, with most studies focusing on 
healthy individuals participating in research. A quantitative study analyzing healthy individuals 
who participated in a genome sequencing study reported that participants perceived genomic 
uncertainty as a quality of the information, citing probability and ambiguity as common factors of 
scientific knowledge. The participants who expected uncertainty from the genomic information 
they would receive typically appraised the uncertainty as an opportunity, while those who did not 
expect uncertainty appraised it as a threat (Biesecker et al, 2014).  
A qualitative study of healthy adults and adult cardiology patients enrolled in a genome 
sequencing study were asked questions about their perceptions of VUSs before they underwent 
genome sequencing. Expectations about VUSs were mixed. Some expected VUSs from genome 
sequencing because of previous experiences with medical uncertainty or an understanding of the 
limitations of medical science, while others were surprised that an uncertain finding could exist 
from genome sequencing. Regarding medical action, some reported they would prioritize healthy 
behaviors if they received a VUS while others reported they would not focus on the VUS because 
their doctors would be uncertain about its health implications. Most participants were optimistic 
that the uncertainty associated with a VUS would be reduced by future scientific discoveries 
(Jamal et al, 2017). These studies underscore the importance of prior expectations, as they may 






Responses to Genomic Uncertainty: Variants of Uncertain Significance and 
Uninformative Negative Results. Studies describing adult patient perceptions and responses to 
genomic uncertainty have mainly focused on VUSs and uninformative negative results from 
single gene or gene panel tests in the context of hereditary cancer diagnoses. For example, it has 
been reported that about a third of patients who receive VUSs from BRCA1/2 testing recall their 
test results inaccurately (Richter et al, 2014; Vos et al, 2008). Richter and colleagues reported that 
patients who received VUSs from BRCA1/2 testing responded to their results more similarly to 
those who received negative test results than those who received positive test results in terms of 
risk perception, cancer worry, and uptake of surveillance and risk-reducing surgeries (Richter et 
al, 2014). Vos and colleagues reported that patients who received VUSs from BRCA1/2 testing 
felt little general life impact, yet about a third reported changes in surveillance behavior and 
medical decisions. Surprisingly, they also found that most patients simultaneously recalled their 
VUS as non-informative but interpreted it as pathogenic, showing that an incongruent perception 
may act as a coping mechanism to reduce uncertainty (Vos et al, 2008). A similar incongruence 
was found in a study of adult cancer patients who received VUSs from cancer gene panel testing. 
Most participants reported high perceptions of certainty about their VUS yet had accurate recall 
and interpretations of their result as being a VUS (Bonner et al, 2017). Solomon and colleagues, 
in their qualitative study interviewing patients with inherited risk for colorectal cancer, found that 
most patients receiving VUSs from colon cancer panels had accurate recall, but varied in their 
conceptualization of uncertainty and emotional response. Both positive and negative appraisals 
were given to their VUS, resulting in a variety of coping strategies (Solomon et al, 2017).  
A qualitative study of women who received uninformative negative BRCA1/2 results 
found that the genetic test results were interpreted in multiple ways depending on the individual’s 
beliefs about the adequacy of testing and family history of cancer. While all women described 





carried an undetected variant while others believed their cancer had no genetic basis (Maheu & 
Thorne, 2008). A quantitative study of women who received uninformative negative BRCA1/2 
results found that women who reported high ratings of pretest perceptions of carrying a cancer-
related variant were at an increased risk for sustained distress (O’Neill et al, 2009). A different 
quantitative study found that some women who received uninformative negative BRCA1/2 results 
experienced worry or distress up to seven months after testing, and that distress and worry were 
directly related to personal cancer history (van Djik et al, 2006). It is important to note that these 
studies about uncertain negatives were all based on genetic testing of only the BRCA1/2 genes; 
responses to uncertain negatives in cancer genetic testing might differ in the context of broader 
panel tests. 
One qualitative study of patient responses to negative results from exome sequencing 
sampled adult patients and parents of child patients, as well as the genetics providers who 
returned their results, to explore the interactions that occurred during result disclosure and how 
patients and parents construct meaning around their results. One month post disclosure, patients 
and parents held the same interpretation about their results as constructed in the disclosure 
session, which was context-dependent and varied based on the provider’s interpretation of the 
result and personal values.  After one month, most patients and parents felt either reassured that 
there was no genetic cause to be found or felt promise around the potential for future technology 
to discover a genetic cause (Skinner et al, 2016).  
In addition, another study has analyzed patient responses to clinically uncertain variants 
from exome sequencing (these variants included VUSs, two pathogenic variants with uncertain 
phase (cis or trans), and variants with uncertain or incomplete phenotypic fit for the patient’s 
condition). It should be noted that for the non-VUS results included in this study, providers 
described these results as “uncertain but likely” or “uncertain but possible,” illustrating that these 





VUSs. This qualitative study also sampled adult patients and parents of child patients, as well as 
the genetics providers who returned their results, to explore the interactions that occurred during 
result disclosure and how patients and parents respond to their results. Most patients and parents 
understood their result was uncertain, yet they had various levels of detailed recollection about 
the degree of uncertainty or the type of result. Overall, patients and parents reported feeling 
prepared for an uncertain result and most regarded their result as having potential value in the 
future (Skinner et al, 2018). 
Previous studies analyzing patient responses to clinically uncertain results present 
inconsistent conclusions, with some studies reporting mostly accurate recall and some reporting 
significant inaccurate recall (Richter et al, 2014; Vos et al, 2008; Vos et al, 2008; Bonner et al, 
2017; Solomon et al, 2017). In addition, risk perception can be congruent or incongruent with 
accurate recall. These studies most frequently focus on VUSs and uninformative negative results 
from cancer gene testing, and their conclusions may not be generalizable to patient populations 
who seek exome sequencing, such as patients with undiagnosed conditions. Conceptualizations of 
illness uncertainty suggest that responses to clinically uncertain results from exome sequencing 
may be different from what we know about how patients respond to clinically uncertain results 
from more targeted tests.  
Illness Uncertainty and Ambiguity Aversion. Illness uncertainty, or a state in which one 
lacks the ability to “explain the cause of an illness, define an illness, or make predictions about 
future health,” has been shown to influence perceptions of exome sequencing. In a study of adult 
patients with undiagnosed conditions, illness uncertainty was shown to influence an individual’s 
perception of the benefits of exome sequencing and the types of information they would hope to 
learn from exome sequencing. Specifically, illness uncertainty was shown to be a major motivator 
in the decision to pursue exome sequencing. Those who felt more illness uncertainty hoped to 





sequencing. Those who felt less illness uncertainty perceived the major benefits of exome 
sequencing as gaining information about familial recurrence risks and prognostic information for 
family members (Khan et al, 2015).   
Ambiguity aversion is a personality trait that influences how one might approach 
uncertain information. Those with ambiguity aversion experience negative appraisals of 
uncertainty and avoid making decisions when they encounter ambiguity. Ambiguity aversion has 
been reported to be associated with lower intentions to learn more about or share exome 


















OBJECTIVES AND SPECIFIC AIMS 
The demand for clinical exome sequencing is outpacing the developments necessary for 
more comprehensive genetic variant interpretation, thus resulting in growing diagnostic 
uncertainty from exome sequencing results. This genomic uncertainty may only be reduced when 
the medical community has more data about the disease-causing potential of exonic variants 
(Newson et al, 2016). There is only a small body of literature focusing on how patients respond to 
uncertain genomic information. These studies prioritize parents of children with undiagnosed 
conditions and patients who seek cancer gene testing and are not necessarily generalizable to 
patient populations seeking exome sequencing. The purpose of this exploratory study was to 
understand the experiences of adult patients with undiagnosed conditions who have received two 
of the more common types of clinically uncertain results from exome sequencing: either a 
negative result, or a result with one or more VUSs.  
Aim 1: To understand how adult patients with undiagnosed conditions recall and perceive 
their clinically uncertain result from exome sequencing. This aim explored the extent of the 
patients’ recall of their clinically uncertain result, including their understanding of the limitations 
of a clinically uncertain result due to its uncertain nature. It also explored how patients 
conceptualize the uncertainty related to their clinically uncertain result, as well as their 
perceptions of the relationship between their clinically uncertain result and the cause of their 
condition.  
Aim 2: To describe common affective and behavioral responses adult patients with 
undiagnosed conditions report when receiving a clinically uncertain result from exome 
sequencing. This aim explored how patients describe and categorize their emotional reactions to 
receiving clinically uncertain result from exome sequencing. It also explored how patients 






Aim 3: To compare the experiences of patients who received a clinically uncertain negative 

























Participants were adult patients with undiagnosed conditions who have received one of 
the more common types of clinically uncertain results from exome sequencing: either a negative 
result or one or more VUSs. Participants were recruited from Johns Hopkins Hospital Genetics 
Clinics (JHHGC) and Kennedy Krieger Institute (KKI). The following were the eligibility 
criteria. 
 
Inclusion criteria:  
 Had endured a diagnostic odyssey of at least six months before receiving exome 
sequencing. A diagnostic odyssey may be defined as (1) having a set of clinical 
symptoms but no diagnosis, (2) having a clinical diagnosis of a broad category of disease 
(i.e. ataxia, muscular dystrophy) but no specific diagnosis, or (3) having a clinical 
diagnosis composed of psychosomatic and/or descriptive diagnoses that individually 
define single symptoms or groups of symptoms (i.e. migraines, IBS, joint pain), but that 
do not explain the entire phenotype. 
 And Had exome sequencing in an attempt to attain a specific molecular diagnosis.  
 And Received post-test counseling for exome sequencing by a genetic counselor.  
 And Received a clinically uncertain result (a negative result with no reported genetic 
variants OR one or more VUSs) from exome sequencing.  
 And Result disclosure for exome sequencing occurred anywhere from one week to seven 








Exclusion criteria:  
 Exome sequencing results provided a molecular diagnosis for the patient that does not 
fall into one of the above inclusion categories.  
 Patient was under age 18 years at the time of clinically uncertain result disclosure. 
 Patient has a cognitive disability that prevents him/her from comprehensibly answering 
interview questions. 
 Patient cannot speak or understand English.  
 
Procedures 
Patients from JHHGC and KKI who met eligibility criteria were identified from 
institutional databases by the genetic counselors at each recruitment site. The genetic counselors 
first contacted these patients to ask for permission for their name and contact information to be 
shared for recruitment outreach by the lead investigator, AN (see recruitment script for genetic 
counselors in Appendix B). Eligible patients were contacted by AN by phone, email, or mail for 
recruitment. They were sent or told information about the purpose and procedures of the study 
(see recruitment materials in Appendices C, D, and E). Interested patients were then sent a 
consent form and two short questionnaires, and phone interviews were scheduled (see consent 
form and questionnaires in Appendices F, G, H, and I).  The questionnaires were the Intolerance 
of Uncertainty Short Form Scale (Carleton et al, 2007) and the Perceptions of Uncertainties in 
Genome Sequencing (PUGS) Scale (Biesecker et al, 2017).  Participants were instructed to 
answer the questionnaires in preparation for the interview. During the phone interview, AN asked 
the participant to read aloud their responses to the questionnaires and she recorded the responses 
on a form. The questionnaire responses were used to characterize the study sample.  
Intolerance of Uncertainty Short-Form Scale: Intolerance of uncertainty is “the tendency 





irrespective of the probability of occurrence.” Individuals with a higher intolerance of uncertainty 
tend to worry more and feel more anxious (Carleton et al, 2007). The Intolerance of Uncertainty 
Short Form Scale is a 12-item scale. The items on the scale are questions that address how one 
might feel in a common uncertain situation. The questions are framed with a Likert scale ranging 
from 1-5, with 1 being “Not at all characteristic of me” and 5 being “Entirely characteristic of 
me.” Higher scores convey greater intolerance of uncertainty.  
PUGS Scale: The PUGS scale measures “patients’ perceptions of uncertainties regarding 
the clinical, affective, and evaluative implications of genome sequencing results.” Specifically, 
this scale has items that evaluate individuals’ perceptions of ambiguity, ambivalence towards 
learning results, medical ambiguity aversion, and uncertainty after result disclosure (Biesecker et 
al, 2017). The PUGS scale is a 10-item scale. The items on the scale are questions that address 
feelings of certainty about different aspects of a genetic test result. The questions are framed with 
a Likert scale ranging from 1-5, with 1 being “Very Uncertain” and 5 being “Very Certain.” 
Higher scores convey greater certainty in patients’ perceptions of their genome sequencing 
results.  
When signed consent forms were returned to AN, the genetic counselors at each 
recruitment site provided her with the following clinical information about their patients: 
clinically uncertain result type (either VUS or uncertain negative - but not information about the 
specific genetic change(s)), number of days between the date the patient elected exome 
sequencing and the date the patient received their results, and the month and year the patient 
received their exome sequencing results. Participants consented to this information being shared 
with the study team by signing the consent form. 
Phone interviews were only conducted if participants returned their signed consent form.  
Phone interviews were conducted solely by AN between August and October of 2018. Interviews 
typically lasted 45-60 minutes and began with the collection of demographic information and 





interview guide, which focused on the experience of receiving a clinically uncertain result from 
exome sequencing, with emphasis on conceptualization of uncertainty, coping, and other affective 
and behavioral responses. The interview guide was developed based on the specific aims of the 
study as well as interview guides from existing similar qualitative studies. It was driven by open-
ended questions, but included specific prompts to elicit more specific information from the 
participants (see interview guide in Appendix J). After the first few interviews were completed, 
the interview guide was adjusted slightly by reframing certain questions and changing the order 
of a few questions to enhance clarity, improve the flow of the interview experience, and better 
elicit information from participants. 
 
Data Analysis 
Interviews were audio-recorded and transcribed by an outside transcription company. 
Transcripts of interviews were explored solely by AN using thematic analysis, which allows for 
the identification of common themes and patterns within the interview transcripts. First, coding 
was conducted using NVivo, a qualitative data analysis software. A preliminary codebook of a 
priori codes was created based on topics from the interview guide, such as “hopes and 
expectations,” “coping,” and “recall and understanding.” This preliminary codebook was applied 
to several initial transcripts from both participants who received negative results and those who 
received VUSs to confirm the codebook applied to both groups of transcripts. While applying the 
a priori codes to the first set of transcripts, some emerging codes were identified and added to the 
codebook, such as “motivations,” and “feeling differently about cause of condition.” Once the 
initial codebook of a priori and emerging codes was established from coding the initial 
transcripts, sub-codes were created for various codes and the initial coded transcripts were re-
coded to include the sub-codes. The final codebook was then used to code the remaining 
transcripts. AN met periodically with her committee members during the coding process to 





point in which no additional concepts or codes can be found in the data, was confirmed by the 
final codebook remaining stable during the process of coding the remaining transcripts (Hennink 
et al, 2017). 
Once coding was completed, findings were interpreted via thematic analysis. First, coded 
data was separated into various groups for multiple types of comparative analysis, in which 
grouped data was analyzed side by side to detect any possible differences in emerging themes. 
The comparative groups were as follows: VUSs vs. negative exome sequencing results, “high” vs. 
“low” responses to the questionnaire data, and shorter vs. longer time since result disclosure. 
“High” and “low” groups for responses to questionnaire data were created based on the median 
score possible for each questionnaire (PUGS possible median score is 30, “low” = responses 10-
29, “high” = responses 30-50; Intolerance of Uncertainty possible median score is 36, “low” = 
responses 12-35, “high” = responses 36-60). Shorter time since result disclosure was defined as 
one week to 12 months, and longer time since result disclosure was defined as greater than 12 
months. As a whole, the coded data was then reviewed and grouped into potential themes. 
Potential themes were refined by providing clear names and definitions and assessing how each 
theme was related to the overall data set and the specific aims of the study. Themes were 
analyzed within the context of participants’ diagnostic odysseys. Coded data within each theme 












A total of 32 participants were contacted during recruitment. Twenty-seven individuals 
were reached during recruitment and expressed interest in participating in the study. They were 
sent consent forms and had interviews scheduled. Four of these 27 individuals either did not 
return their consent form or were unable to be reached for the phone interview. Therefore, the 
response rate was 72% (23/32). Of the 23 total participants, 12 were recruited from JHHGC and 
11 were recruited from KKI. Twenty-three interviews and questionnaires were collected; 14 were 
from participants with VUSs and 9 were from participants with negative results. One interview 
from a participant with a VUS was dropped from data analysis because the interview revealed 
that his exome sequencing results provided him with a diagnosis. 
Participants had exome sequencing between 2014 and 2018. The study sample was 
mostly Caucasian (n=22), over half were male (n=14), and the sample was fairly well-educated. 
Participants widely varied in their intolerance of uncertainty and perceptions of genomic 













Table 1 Demographics and characteristics of the study participants. 
Characteristic Participants with VUSs 
Result (N=14) 
Participants with Negative 
Result (N=9) 
Age at Time of Recruitment, Range 28-69 29-71 
Male, % 79% (11/14) 33% (3/9) 
White, % 91% (13/14) 100% (9/9) 
Estimated Annual Household Income <$45,000                         2 
$45,000-$89,999             1 
 ≥$90,000                      10 
Declined to answer          1 
  <$45,000                          3 
  $45,000-$89,999              1 
  ≥$90,000                          5 
Education Graduate School              8 
College Graduate            5 
Some College                  1 
High School                    0 
  Graduate School               1 
  College Graduate             6 
  Some College                   1 
  High School                     1 
Length of Diagnostic Odyssey 6 months – 1 year            1 
3-4 years                          5 
5-10 years                        2 
over 10 years                   6 
  6 months – 1 year             0 
  3-4 years                           2 
  5-10 years                         5 
  over 10 years                    2 
Approximate Time Passed Since Exome 
Result Disclosure, Range 
1 month – 4.25 years 6 months – 2.5 years 
Category of Undiagnosed Condition
3
 Neurologic/Ataxia           7  
Myopathy                        3 
Cardiovascular                1  
Connective Tissue           1  
Ambiguous                      2  
  Neurologic/Ataxia            3 
  Myopathy                         2 
  Cardiovascular                 1  
  Connective Tissue            0 
  Ambiguous                       3  
Intolerance of Uncertainty Short-Form 
Scale
1
, mean (SD) 
25.9 (8.34) 30.4 (8.50) 
Perceptions of Uncertainties in Genome 
Sequencing Scale
2
, mean (SD) 
36 (9.90) 32.2 (6.38) 
1. Intolerance of Uncertainty Short Form Scale: Higher scores convey greater intolerance of uncertainty. Range: 16-48  
2. Perceptions of Uncertainties in Genome Sequencing Scale: Higher scores convey greater certainty in patients’ 
perceptions of their genome sequencing results. Range: 20-50 
3. Based solely on participant report of their symptoms. Ambiguous refers to a symptomatology that does not fit into 
one distinct category. 
 
 
All participants had unique stories about how they ended up having exome sequencing. 
Some self-referred themselves to the genetics clinic after doing online research or searching for 
recommendations on advocacy or support group websites. Others were simply referred by a 





No thematic differences were detected during comparative analysis, which further 
confirmed data saturation within the total data set. Interviews uncovered four major themes: 
conceptualizations of uncertainty, acclimation to illness uncertainty, hope, and optimism. 
 
Conceptualizations of Uncertainty 
  Participants generally had an accurate understanding of their clinically uncertain results. 
Those with negative results could articulate that there were no reportable findings through 
conveying that ‘the test found nothing’ or that they had not learned anything new about their 
condition from their results. For example, one participant described the takeaway message she 
understood of her negative result: 
“But I guess what I came away with was it was another sort of dead-end 
because I didn’t get any results.” (P5, Negative, Ambiguous) 
Twelve of the 13 participants with VUSs could describe that exome sequencing detected 
something that their genetics providers could not say with certainty explained their condition at 
the current time. Yet when demonstrating this conceptual understanding of a VUS, only one 
participant recalled the term “variant of uncertain significance” when asked about the ‘type’ or 
‘classification’ of their exome sequencing result (she reported that she only remembered the term 
because she recognized it on the consent form for our study). Instead, a variety of other terms 
were used to describe the VUSs. For instance, one participant described his VUSs as uncertain 
“abnormalities:” 
"There's nothing definitive here but we do see some abnormalities that if 
we were to potentially take a deeper dive, or in future advancements in 
the studies, they might be able to tell." (P17, VUSs, Neurologic/Ataxia) 






“They found some things that were slightly unusual but they did not 
know what those were an indication for.” (P24, VUSs, Neurologic/ 
Ataxia) 
The fact that the term “variant of uncertain significance” was not memorable may suggest that the 
phrase itself is not necessary for adult undiagnosed patients to comprehend the nature and 
implications of this type of result.  Almost all participants did not use genomics jargon but instead 
chose layman terms to describe their VUSs. While these words do not precisely define what a 
VUS is, the participants still demonstrated a conceptual understanding that their result was an 
uncertain finding that their genetics providers could not use to provide a diagnosis. Regardless of 
the type of result, all participants had at least a gist understanding that their exome sequencing 
result was clinically uncertain, therefore not providing a molecular diagnosis, a prognosis, or any 
guidance related to treatment or management of symptoms.  
The participants conceptualized the uncertainty related to their exome sequencing result 
in multiple ways. These conceptualizations can be described using Han and colleagues’ taxonomy 
of genomic uncertainties (Han et al, 2017). Participants identified probability uncertainty through 
their understanding that their exome sequencing result did not provide prognostic information. 
One participant expressed this probability uncertainty when describing how her hope for a 
prognosis by exome sequencing was not met: 
“I was hopeful that I would have an explanation and that we would be 
like, ‘Well, this is it, and this is what’s going to happen, and this is how 
your life is going to be.’ But that didn’t happen.” (P1, VUSs, 
Neurologic/Ataxia) 
Ambiguity uncertainty was marked by the participants’ understanding that current genomics 
knowledge is not advanced enough to provide a diagnosis from exome sequencing. One 






“Although they don’t know what they don’t know, either.  There’s always 
a possibility there could be something there, but they just don’t know.” 
(P19, Negative, Neurologic/Ataxia) 
Some participants perceived a nonexistent recurrence risk for their undiagnosed condition based 
on their clinically uncertain result. They did not demonstrate an understanding that despite not 
having a molecular diagnosis by exome sequencing that there is still the possibility for hereditary 
transmission of their condition. For instance, when asked about what implications his clinically 
uncertain result had for family members, one participant said about recurrence risk: 
 “Well, I was concerned about family members, and how it might affect 
any nieces or nephews, brothers or sisters, and I was assured that that 
would not be the case based on what they learned from the exome 
sequencing.  So that was good.  That was a relief.” (P9, VUSs, 
Myopathy) 
This misunderstanding of a more nuanced genetics concept may reflect complexity uncertainty, as 
this aspect of their result is challenging to understand. However, it may also reflect a desire for 
the clinically uncertain result to have some useful meaning or a realization that their result rules 
out some number of known heritable conditions.  
Uncertainty was also conceptualized as a ‘lack of identity,’ which may fall under person-
centered issues of uncertainty in Han and colleague’s taxonomy. For many participants, being 
undiagnosed meant that a significant part of their identity was undefined, which could feel 
isolating. Receiving a diagnosis would mean achieving that missing identity and being able to 
join an identifiable group of members with the same known condition. Being a part of such a 
group has certain benefits, like access to support groups and the ability to qualify for participation 
in research studies. When asked directly about participation in support groups and research 





status made them difficult to find. For example, one participant described the challenge of finding 
the right support group: 
“As far as support groups or whatever it's kind of difficult because I 
don't fit in with anyone. I'm unique.” (P5, Negative, Ambiguous) 
 Babrow’s forms of uncertainty can also be used to describe how our participants 
experienced the uncertainty from their exome sequencing result (Babrow, 1998). For instance, 
structuring of information denotes how an individual integrates genomic information into their 
existing beliefs. Regarding the effects of clinically uncertain results on beliefs about the cause of 
their undiagnosed condition, most participants reported that their exome sequencing result 
reinforced their previous belief that their condition had either a genetic or non-genetic cause. For 
instance, one participant’s VUS reinforced her belief that her undiagnosed condition had a genetic 
cause. She described her VUS as being in only one allele of a gene known to cause an autosomal 
recessive condition that is similar to her constellation of symptoms. She expressed that she 
believes she has a milder version of this recessive condition that is caused by her single genetic 
variant. She believes that in the future, geneticists will learn that a milder form of her condition 
can be caused by a single allelic pathogenic variant. She explained:  
“I guess it makes me more confident that there is a genetic explanation, 
as strange as that sounds.  I do think that it's not a coincidence that I 
have this one defective gene that's related to [name of condition].  Even 
though they don't think that the characteristics are expressed if you only 
have one gene, I think that maybe there's something that they just don't 
know, maybe [I] don't have the full [name of condition].  So to me it 
confirms that there's something there; they just haven't quite figured it 
out yet.” (P18, VUSs, Connective Tissue) 
On the other hand, participants also spoke about how their clinically uncertain result reinforced 
the belief that the cause of their undiagnosed condition was non-genetic. For example, one 





caused by rare side effects of a medication he once took to regulate his cholesterol (P3, VUSs, 
Myopathy). Another participant shared how his VUS reinforced his belief that Lyme disease 
explained his undiagnosed condition (P12, VUSs, Cardiovascular). Finally, a participant spoke 
about how her clinically uncertain result reinforced her belief that her condition is non-genetic 
because no one else in her family has similar symptoms: 
“I think it's most likely not genetic because nobody else that I've ever 
heard of in a hundred relatives has ever had it.  And I know it can be a 
spontaneous genetic issue, that this can start with me-- I understand that-
- but for some reason I just don't think it is.” (P20, Negative, 
Neurologic/Ataxia) 
Babrow’s term inherent uncertainty describes the uncertainty that arises from the 
undiagnosed condition itself. Most participants reported that their clinically uncertain result 
reminded them of the inherent uncertainty of their undiagnosed condition, specifically the 
uncertainty around cause, prognosis, and treatment or cure. The response to remembering this 
inherent uncertainty during result disclosure was described by most participants as 
disappointment or frustration. For example, one participant described how each inconclusive test 
result received during her diagnostic odyssey makes her feel frustrated: 
“I'm kind of used to the frustration, but it is a little frustrating that every 
time I go in, they're like, ‘Oh, you've got this, this, this, this,’ but they 
don't really know.” (P14, Negative, Ambiguous) 
Another participant described her disappointment about exome sequencing not 
resolving the inherent uncertainty of the cause of her condition: 
“I was totally disappointed because I wanted an answer and I thought, 
you know, I don't even care if I'm diagnosed with something, I just want 






Acclimation to Illness Uncertainty  
 According to Mishel’s uncertainty in illness theory (UIT), individuals who experience 
chronic illness uncertainty ultimately believe that certainty and predictability regarding their 
condition are unrealistic (Mishel, 1990). Our participants’ expectations about exome sequencing 
relieving some of their illness uncertainty aligned with the UIT. All participants expressed a 
belief that exome sequencing was unlikely to provide results that relieved illness uncertainty. In 
other words, they expected a clinically uncertain result rather than one that would provide a 
diagnosis, prognosis, or information about treatment for their condition. While many participants 
mentioned that their genetics provider was diligent about informing them of the small likelihood 
of a diagnostic result during pre-test counseling, participants mostly contributed their 
expectations about clinically uncertain results to having a history of receiving inconclusive 
medical test results during their previous diagnostic experiences. One participant illustrated how 
her diagnostic odyssey influenced her expectations: 
“What I think of in the course of battling this for almost 20 years I’ve kind 
of learned to lower my expectations and not expect a lot.” (P5, Negative, 
Ambiguous) 
 
Essentially, participants were used to receiving inconclusive medical tests results, and therefore 
expected their exome sequencing result to also be inconclusive. 
 This expectation of continued illness uncertainty was also revealed when participants 
were asked about their initial emotional response to receiving their clinically uncertain result. 
Some participants expressed that their response was neutral because they expected an 
inconclusive result and are used to receiving these types of results from medical tests. For 





“I didn't have a huge reaction to it because it said what I expected it to 
say… But it didn't upset me; it didn't really have any negative effects, nor 
a positive effect because it didn't really tell me anything.  So I guess I'd 
say I had a fairly neutral reaction to it.” (P11, VUSs, Myopathy) 
 
Being acclimated to illness uncertainty allowed participants to more easily accept and 
move on from the additional uncertainty added by this most recent clinically uncertain result. 
When describing their coping strategies for dealing with the uncertainty from their exome 
sequencing result, many participants reported the use of acceptance. Specifically, the phrase “it is 
what it is” was used quite often to express the acceptance of the uncertainty related to their 
exome sequencing result and subsequently their undiagnosed condition. This phrase also seemed 
to capture the sentiment of being acclimated to illness uncertainty. One participant described 
being able to easily accept his clinically uncertain result because he has received those types of 
results in the past: 
“I’ve grown accustomed to receiving that, ‘Oh we don’t know what it is,’ 
kind of diagnosis. I’m just like, let’s just move on…” (P6, VUSs, 
Neurologic/Ataxia) 
 
Many expressed spending limited or no time dwelling on their exome sequencing result or 
“moving on” from their result disclosure experience relatively quickly because their result had 
little impact on their lives or understanding of their condition. One participant articulated this 
acceptance by saying: 
“I have the same information that I had at the time, which is kind of a 
non-answer… and it's still that way. […] No, I don't really spend time 
thinking about it.” (P18, VUSs, Connective Tissue) 
 
This minimal impact of their clinically uncertain result explains why most participants did not 





participant simply explained why he feels the same about his clinically uncertain result two and a 
half years after receiving it: 
“So that's why my attitude […] hasn't changed because nothing new 
came up to affect anything.” (P26, Negative, Myopathy) 
 
Hope  
Despite participants universally expecting that it was unrealistic for exome sequencing to 
relieve illness uncertainty, all participants still hoped that it would. Participants’ primary 
motivation for electing exome sequencing was driven by their residual hope that the genetic test 
could provide a diagnosis. How a diagnosis could specifically relieve illness uncertainty was 
different for different participants. Some hoped that a diagnosis could provide clarity about the 
chance that other relatives would inherit their condition. When describing his motivations and 
hopes for electing exome sequencing, one participant said: 
 “It was just knowing that this condition that I have wouldn’t be passed 
on to my children.  That was basically-- for me, that’s what I was hoping 
to hear from it…” (P19, Negative, Neurologic/Ataxia) 
Others hoped that a diagnosis would relieve prognostic uncertainty or provide specific guidance 
for treatment or management of symptoms. For example, when describing his hopes for what 
exome sequencing could provide, one participant said: 
“I think information that […] could help me have a better idea of what 
might be going on with me and help plan for the current and the future I 
think would be beneficial.” (P9, VUSs, Myopathy) 






“Well, I was willing and anxious to do anything that might lead to a 
proper diagnosis and then a treatment program that might reverse the 
decline that I was experiencing in the muscles in my back.” (P26, 
Negative, Myopathy) 
Finally, some hoped that a diagnosis could make them eligible to participate in clinical trials 
related to their condition. Participation in these studies meant contributing to efforts aimed at 
relieving uncertainty about their undiagnosed condition. 
 Participants also expressed hope regarding the promise of newer technologies or 
advances in genomics knowledge aiding in relieving illness uncertainty in the future. This hope 
was expressed in two different ways. First, it was expressed in the context of participants 
understanding the limitations associated with the exome sequencing test. While many described 
exome sequencing as being the most comprehensive genetic diagnostic test available, some 
demonstrated the additional understanding that the test’s diagnostic utility only stretches as far as 
the current state of genomics knowledge. In other words, some understood that there may still be 
a genetic explanation for their condition that has yet to be discovered, but exome sequencing is 
not able to detect it at this time. For example, one participant demonstrated an understanding of 
this concept when discussing what he learned during pre-test counseling: 
"Just because it's not there, there's other genes that we haven't unlocked 
yet that may be causal." (P23, VUSs, Neurologic/Ataxia) 
This more nuanced understanding of a limitation of exome sequencing may be explained by the 
fairly well-educated demographic of our sample or detailed pre-test counseling. Nevertheless, this 
understanding reflects hope in advances in genomics knowledge producing a diagnosis in the 
future. Second, hope was expressed in the context of motivations for electing exome sequencing. 
Specifically, some participants were motivated to have exome sequencing because they knew 
their genetics provider could reanalyze their exome sequencing results or genomic data in the 





“Sometimes new medical science goes on, they get new, more 
information about causes of ataxia or places it can be, genes it can be in, 
and sometimes they like to retest things, and sometimes they actually get 
a diagnosis on the second testing…” (P20, Negative, Neurologic/Ataxia) 
This motivation demonstrates hope that reanalysis may provide a molecular diagnosis in the 
future. Participants who expressed hope in these two ways illustrate how hope for a diagnosis 
may persist despite the disappointment and frustration that is associated with receiving a 
clinically uncertain result or despite acclimation to illness uncertainty. This persistent hope was 
often reported as a coping mechanism for dealing with the uncertainty not only of their exome 
sequencing result but of their undiagnosed condition. For instance, when describing long-term 
coping with uncertainty, one participant said:  
 “[I’m] Optimistic that technology is advancing so much that I feel 
somewhat confident that I’ll get some answers sooner rather than later.” 
(P9, VUSs, Myopathy)  
Another participant explained how she uses hope as a coping strategy: 
“…there’s hope in science. And the genetic field is just kind of exploding 
and taking off. There's so many new developments and discoveries and 
ways that they're using the information that they’re gleaning that it's very 




Participants described optimism as another coping strategy for dealing with uncertainty 
related to their exome sequencing result and their undiagnosed condition. Many participants 
explicitly mentioned having positive attitudes, while others demonstrated optimism through 





participant explained how surviving many cardiac events helped him to learn to be grateful for 
each day, a lesson that he feels not many people learn: 
“I'm just trying hard to be a glass-half-full guy-- but I consider this 
whole episode to be an absolute gift to me because I'm a healthy, active, 
middle-aged guy, and I've had these near-death experiences and I walked 
away, and I'm still a healthy, active, middle-aged guy, and I can do 
everything that I want to do, and I've been reminded that […] tomorrow 
is not promised, and live for today, and I wake up in the morning every 
morning and I'm happy just because I wake up, and I think a lot of 
people don't get to enjoy that.” (P12, VUSs, Cardiovascular) 
Another participant consistently brought the conversation back to his optimistic 
spirit when describing his response to his clinically uncertain result, saying: 
“I just stay positive about life. There’s enough bad stuff and, like I said, 
a lot of people are dealt some unfortunate things, much worse than me.” 
(P9, VUSs, Myopathy) 
 Participants also demonstrated optimism through describing their emotional responses to 
and perceptions of the meaning of their clinically uncertain result. For example, positive attitudes 
were expressed when participants, like these two, reported feeling relief or happiness that exome 
sequencing, while not providing a diagnosis, at least did not detect a terminal diagnosis or ruled 
out some terminal or severe diagnoses:  
“I mean, I guess I would rather not have an explanation for what has 
happened to me than to say, ‘Oh, you have brain cancer,’ or ‘You have 
this.’  So I was very happy in a way…” (P1, VUSs, Neurologic/Ataxia) 
“…it's good to rule out all the really bad stuff and no causative 
mutations.” (P13, Negative, Cardiovascular) 
A few participants also reported relief and happiness related to exome sequencing not detecting 





not directly relieve diagnostic uncertainty, optimism is employed by some individuals to feel that 
exome sequencing somehow indirectly relieves some illness uncertainty by ruling out certain 
diagnostic possibilities or confirming some level of healthiness. These types of positive responses 
to clinically uncertain exome sequencing results reveal how optimism can be used as a coping 






















The purpose of this study was to explore and describe the experience and impact of adult 
patients with undiagnosed conditions receiving clinically uncertain results from exome 
sequencing. Participants demonstrated a variety of conceptualizations of the uncertainty related to 
their exome sequencing result and undiagnosed condition. They were generally acclimated to 
illness uncertainty due to their lengthy and ongoing diagnostic process, which resulted in realistic 
expectations about and acceptance of their clinically uncertain results. However, participants still 
hoped that exome sequencing would end their diagnostic odyssey, and many remain hopeful that 
future technological advances will provide them with a diagnosis. This residual hope, as well 
optimism, were used as coping strategies to deal with uncertainty. Optimism was particularly 
demonstrated through the use of self-enhancing evaluations. Taylor’s theory of cognitive 
adaptation emphasizes that adaptation to illness uncertainty is partly accomplished by these self-
enhancing evaluations, which help restore an individuals’ self-esteem and perception of self-
control (Taylor, 1983). 
Code saturation was reached within the study sample, and analysis demonstrated that 
there were no thematic differences between coded data from participants who received negative 
exome sequencing results vs. that from those who received VUSs. This finding suggests that adult 
patients with undiagnosed conditions may likely have similar affective and behavioral responses 
to receiving a clinically uncertain result from exome sequencing regardless of the type of result. It 
appears that the type of inconclusive result has little influence on how adult undiagnosed patients 
conceptualize and cope with the genomic and illness uncertainty their result encompasses. 
Instead, the inconclusive nature of negative results and VUSs is equivalent, in that either way the 
result provides no diagnostic or prognostic clarity.  
Participants’ responses to the Intolerance of Uncertainty and PUGS scales revealed that 





related to their exome sequencing results. While there were no thematic differences when 
comparing data from participants who scored “high” vs. “low” on these scales, our sample size 
may be too small to detect significant differences between these groups. Nevertheless, this 
finding might suggest that intolerance and perceptions of uncertainty may not influence the ways 
adult patients with undiagnosed conditions cope with and adapt to uncertainty from clinically 
uncertain results from exome sequencing, perhaps because of their acclimation to illness 
uncertainty. This suggestion differs from what we know from other quantitative studies involving 
healthy individuals (Biesecker et al, 2014), and of course, larger-scale quantitative studies would 
need to be conducted to validate such a conclusion.   
Our participants had particularly good recall and understanding of their clinically 
uncertain results from exome sequencing. This finding from our qualitative study differs from 
mostly quantitative studies of cancer patients receiving clinically uncertain results from targeted 
cancer gene panels, which tend to report incongruent recall and understanding (Richter et al, 
2014; Vos et al, 2008; Vos et al, 2008; Bonner et al, 2017; Solomon et al, 2017). Adult patients 
with undiagnosed conditions may have better recall and understanding than cancer patients 
because they are more familiar with illness uncertainty and are used to receiving inconclusive 
medical test results. In contrast, individuals who qualify for cancer genetic testing tend to have a 
strong family history of cancer, which may strengthen perceptions of certainty or act as evidence 
to support expectations for receiving a diagnostic genetic test result rather than a clinically 
uncertain genetic test result.  
Expectations for uncertain genetic test results due to acclimation to illness uncertainty 
have been described in some of the limited number of qualitative studies related to genomic 
uncertainty. For instance, some healthy adults and adult cardiology patients reported expecting 
VUSs from genome sequencing because they had previous experiences with medical uncertainty 





patients reported feeling prepared for an uncertain result after receiving clinically uncertain 
results from exome sequencing. (Skinner et al, 2018). Persistent hope that uncertainty will be 
resolved by future scientific advances has also been found in some other qualitative studies on 
genomic uncertainty. For example, healthy adults and adult cardiology patients reported 
expectations that such advances will aid in reclassifying VUSs from genome sequencing (Jamal 
et al, 2017). In addition, adult undiagnosed patients and parents of undiagnosed child patients felt 
similar hopes after receiving negative exome sequencing results (Skinner et al, 2016). 
The findings from this exploratory qualitative study are not intended to be representative 
of all adult patients with undiagnosed conditions who receive clinically uncertain results from 
exome sequencing. Our participants were fairly well-educated, which may influence their ability 
to more accurately recall and understand their exome sequencing results. Participants were 
recruited from two different clinical sites, adding variation to the genetic counseling they 
received. While this allowed for some diversification in understanding the ways adult 
undiagnosed patients may be influenced by their result disclosure, result disclosure of clinically 
uncertain results by other genetic counselors may differ from the practices of the genetic 
counselors from our two recruitment sites. In addition, our study sample had a wide variety of 
symptomatology of their undiagnosed conditions. While this variety allowed us to capture over-
arching themes, perhaps more nuanced differences may be detected from studying adult 
undiagnosed patients with more similarly presenting undiagnosed conditions. It should also be 
noted that as exome sequencing is offered earlier in the diagnostic process for individuals in the 








PRACTICE IMPLICATIONS & RESEARCH RECOMMENDATIONS  
 The experiences reported from participants in this study have implications for the clinical 
practice of genetic counselors and other genetics providers. This study demonstrated the range of 
emotional responses adult undiagnosed patients may have from receiving a clinically uncertain 
exome sequencing result, from disappointment and frustration to happiness and relief, and many 
felt more than one of these emotions at the same time. Genetic counselors should remain prepared 
to help clients process the variety of emotions they may feel during result disclosure. Our results 
suggest that the chronic uncertainty of a diagnostic odyssey may contribute to adult patients with 
undiagnosed conditions being better prepared for coping with and adapting to the additional 
uncertainty from their clinically uncertain result from exome sequencing. However, continuing to 
set expectations about the larger likelihood of receiving a clinically uncertain result from exome 
sequencing during pre-test counseling is still important. The increasing demand for genetic 
counseling services may result in changes to genetic counseling practice that may eliminate or 
alter pre-test counseling, yet such changes should still incorporate expectation-setting.  
Adult patients with undiagnosed conditions conceptualize the uncertainty of their result 
in a variety of ways. Genetic counselors should explore the ways in which their clients perceive 
this uncertainty to facilitate appropriate meaning-making of their result. Assessing the client’s 
prior beliefs for the cause of the undiagnosed condition and eliciting the experience of their 
diagnostic odyssey may also help in this process, especially if these conversations occur during 
pre-test counseling.  
Reanalysis was acknowledged by participants as an important benefit of undergoing 
exome sequencing and was a source of hope. Many participants understood the opportunity for 
reanalysis of their exome sequencing results or genomic data and maintained the hope that 
technologic advances would someday discover the cause of their condition. The process of exome 





and is often initiated differently depending on the clinic. Sometimes, clinics will only facilitate 
reanalysis if prompted by the patient through a phone call or follow-up visit. Other times, genetic 
counselors or laboratories will initiate reanalysis after a certain number of years have passed after 
initial result disclosure. Regardless, reanalysis requires additional work by genetic counselors or 
the laboratories that conducted the exome sequencing. Genetic counselors must re-contact 
laboratories that do not conduct reanalysis automatically to initiate the process. For genetic 
counselors who partner with laboratories that do not offer reanalysis, they must re-interpret 
exome sequencing results themselves through searches through the literature and genomic 
databases. Reanalysis is an important practice for patients and providers because it may provide 
diagnoses for patients and works to expand the knowledge of genomics. Providers and 
laboratories should do what they can to facilitate reanalysis for their patients and overall practice. 
As exome sequencing becomes more broadly available, genetics clinics and laboratories should 
consider developing systematic plans for conducting reanalysis for all patients who consent to it. 
The process may become more easily automated with the development of reanalysis 
functionalities of genomic databases.  
 Many participants mentioned that they would like to participate in support groups or 
research studies but are unable to find opportunities for which they qualify or fit in. While most 
research opportunities require a diagnosis to qualify for participation, providers may be equipped 
with referrals to research studies like ours, which focus on undiagnosed patient populations. In 
addition, genetic counselors may consider developing and/or facilitating support groups for their 
undiagnosed patients within their clinical centers. They may also offer to connect their 
undiagnosed patients who express a desire to speak with others who are undiagnosed.   
The purpose of this study was to provide a preliminary understanding of how adult 
undiagnosed patients recall, perceive, and cope with the uncertainty from a clinically uncertain 





remain ripe for future studies. Larger-scale quantitative studies on the affective and behavioral 
impacts of clinically uncertain exome sequencing results may provide more generalizable 
information and target specific challenges in coping and adapting to these results that may inform 
intervention studies. As exome sequencing is offered earlier in the diagnostic process for 
individuals in the future, comparative studies about reactions to clinically uncertain results in 
adult patient populations may be warranted. Future studies may also include topics such as the 
impact of other less common types of clinically uncertain exome sequencing results on adult 
undiagnosed patients, as well as the typical practices of genetic counselors in providing pre- and 
post-test genetic counseling to adult undiagnosed patients seeking exome sequencing and 























Appendix A: A Taxonomy of Medical Uncertainties in Clinical Genome Sequencing 
 
I. Sources 
a. Probability: the indeterminacy or lack of predictability of a phenomenon 
b. Ambiguity: the lack of reliability, credibility, or adequacy of information about a 
phenomenon 
i. Conceptual 
1. Model inadequacy: Limitations in the adequacy of models, both 
theoretical (e.g., gene models) or empirical (e.g., animal system 
models), to represent gene-disease mechanisms in humans. 
2. Nosologic inadequacy: Limitations in the adequacy of current 
disease or phenotype classifications. 
ii. Methodological 
1. Sample or data integrity problems: Limitations in laboratory 
samples or processing techniques resulting in diagnostic error. 
2. Test limitations: Inherent constraints in the accuracy or precision 
of laboratory instrumentation or techniques. 
3. Unmeasured factors: Biological factors that affect the phenotype 
but are as yet undiscovered or not assayed. 
4. Procedural variability or error: An attribute that is subject to 
random variation that leaves a variant undetected. 
5. Test misinterpretation: Failure of diagnostic personnel to 
correctly annotate or interpret a result. 
iii. Clinical 
1. Incomplete or conflicting data: Gaps or inconsistencies in family 
history, pedigree, and clinical outcomes. 
c. Complexity: aspects of a phenomenon that make it difficult to analyze or 
comprehend 
i. Multiplicity of Causes 
1. Locus heterogeneity: A single disorder or phenotypic 
characteristic that can be caused by gene mutations in 
heterogeneous genes (e.g., autism). 
2. Complex genetic traits: A single disorder or phenotypic 
characteristic that is determined in a single individual by 
variation at multiple genetic loci (e.g., height) 
3. Non-genetic causation: Non-genetic (i.e., environmental) 
determinants of disorders or phenotypic characteristics, which 
may interact with genetic determinants and often have poorly 
quantified effects. 
ii. Multiplicity of Effects 
1. Pleiotropy: A single gene mutation that causes multiple 
apparently unrelated disorders or phenotypic characteristics. 





1. Gene x Environment Interactions: Whether environmental 
factors will exacerbate or ameliorate manifestations of disease. 
II. Issues 
a. Scientific: data-centered issues 
i. Diagnostic: Unknown condition or risk. 
1. Gene-Phenotype Association: The likelihood that deleterious 
variants in this gene actually cause disease. 
2. Pathogenicity of Variants 
3. Phenotype-Disease Association: The likelihood that a given 
phenotypic manifestation is part of a disease or syndrome. 
ii. Prognostic: Which disease manifestations will or will not arise, how they 
are likely to evolve over time, the rate and tempo of disease. 
1. Individual 
2. Family 
iii. Causal: Underlying factors and mechanisms that determine or explain a 
given genomic variant or its ultimate phenotype. 
iv. Therapeutic: Unknown approach to treatment or prevention of disease or 
risk. 
1. Prevention 
2. Treatment  
b. Personal: person-centered issues 
i. Psychological 
ii. Social 
iii. Financial  
iv. Existential 
c. Practical: systems-centered issues 
i. Structural: Limitations in institutional facilities and resources 
1. Facilities for participating in genomic testing 
2. Facilities for participating in research 
ii. Procedural: Limitations of actions required to access and utilize health 
care services 
1. Genomic testing 
2. Research 
3. Policy development and implementation 
III. Locus 
a. Patient/participant/family 










Appendix B: Recruitment Script for Genetic Counselors  
 
Email/Electronic Medical Records Format: 
Hello (name of participant), 
This is (name of genetic counselor), your genetic counselor from (name of clinic) who provided 
you with a genetic test called exome sequencing back in (year of exome sequencing result 
disclosure). I am contacting you because we have a Masters student, Ahna Neustadt, who is 
interested in interviewing you over the phone for her thesis project. She is doing a project about 
how people like you have experienced receiving exome sequencing test results.  
Ahna would like to contact you to tell you more about her project and how you can participate. If 
you would like for Ahna to contact you, you would need to provide permission for me to give her 
your name, email address, phone number, and current mailing address. After talking with Ahna, 
you can decide whether or not you want to participate in her study.  You would receive a $20 gift 
card after participating in the research project if you decide to take part. 
Please respond to this message stating whether you give me permission to give Ahna your name 
and contact information.  
Thank you for your consideration! 
Best, 
name of genetic counselor 
 
Phone Call Format: 
 
Hi! This is (name of genetic counselor) from (name of clinic). I am calling for (name of 
participant), is this he/she? 
Hi, (name of participant). I am your genetic counselor who provided you with a genetic test 
called exome sequencing back in (year of exome sequencing result disclosure). I am calling you 
because we have a Masters student, Ahna Neustadt, who is interested in interviewing you over 
the phone for her thesis project. She is doing a project about how people like you have 
experienced receiving exome sequencing test results.  
Ahna would like to contact you to tell you more about her project and how you can participate. If 
you would like for Ahna to contact you, you would need to provide permission for me to give her 
your name, email address, phone number, and current mailing address. After talking with Ahna, 
you can decide whether or not you want to participate in her study.  You would receive a $20 gift 
card after participating in the research project if you decide to take part. 
Are you interested in Ahna contacting you for her research project? 
 If they say no: No problem. Thank you for consideration. Have a wonderful day!  Bye. 
If they say yes: Great! You just need to provide me with verbal permission for me to give 





(Participant provides verbal confirmation…) Thank you. I will note your permission in 

































Appendix C: Recruitment Letter - Kennedy Krieger Institute 
 
Dear _______________, 
You are invited to participate in a study conducted by researchers at the National Human 
Genome Research Institute and Johns Hopkins School of Public Health. A main goal of our 
research is to understand how people think, feel, and act after receiving different kinds of genetic 
test results. We are especially interested in understanding how people react to getting these kinds 
of results as part of a search for a diagnosis. You are being contacted because you have had a 
genetic test called an exome sequence through Kennedy Krieger Institute.  
We currently know little about how people react to getting different kinds of genetic test results 
from exome sequencing. The information gained from this study will provide a deeper 
understanding of this experience. In addition, we hope that this study will inform how genetic 
counselors talk about results with their patients.  We also hope that it will help genetic counselors 
better understand how to help patients like you cope with their results. 
This study involves a 45-60 minute phone interview and the completion of 2 short surveys before 
the interview. During the interview, you will be asked questions about your test result. We will 
also ask you to respond to some general questions about yourself. People who take part in this 
study will receive a $20 gift card as payment for their time. 
You may take part in this study if you meet the following: 
1. You were 18 years or older at the time you received your exome sequence test results 
2. You are able to speak and understand English 
3. You are able to consent for yourself and participate in a phone interview 
If you are willing to take part in this study or are interested in receiving more information about 
this study please contact the researchers below by phone or email. If you would prefer that we not 
contact you further, please let us know. We have tried to reach you by phone but have not been 
successful. We will continue to try to reach you by phone if we do not hear directly from you. 

















Lori Erby, PhD, ScM, CGC 
Director, JHU/NHGRI GCTP Training Program 
Adjunct Asst. Prof., Dpt. of Health, Behavior & Society 





Ahna Neustadt, BS 
Graduate Student,  
Genetic Counseling Training Program 








Appendix D: Recruitment Letter - Johns Hopkins Hospital Genetics Clinics 
 
Dear _______________, 
You are invited to participate in a study conducted by researchers at the National Human 
Genome Research Institute and Johns Hopkins School of Public Health. A main goal of our 
research is to understand how people think, feel, and act after receiving different kinds of genetic 
test results. We are especially interested in understanding how people react to getting these kinds 
of results as part of a search for a diagnosis. You are being contacted because you have had a 
genetic test called an exome sequence through Johns Hopkins Hospital Genetics Clinic.  
We currently know little about how people react to getting different kinds of genetic test results 
from exome sequencing. The information gained from this study will provide a deeper 
understanding of this experience. In addition, we hope that this study will inform how genetic 
counselors talk about results with their patients.  We also hope that it will help genetic counselors 
better understand how to help patients like you cope with their results. 
This study involves a 45-60 minute phone interview and the completion of 2 short surveys before 
the interview. During the interview, you will be asked questions about your test result. We will 
also ask you to respond to some general questions about yourself. People who take part in this 
study will receive a $20 gift card as payment for their time. 
You may take part in this study if you meet the following: 
1. You were 18 years or older at the time you received your exome sequence test results 
2. You are able to speak and understand English 
3. You are able to consent for yourself and participate in a phone interview 
If you are willing to take part in this study or are interested in receiving more information about 
this study please contact the researchers below by phone or email. If you would prefer that we not 
contact you further, please let us know. We have tried to reach you by phone but have not been 
successful. We will continue to try to reach you by phone if we do not hear directly from you. 














Lori Erby, PhD, ScM, CGC 
Director, JHU/NHGRI GCTP Training Program 
Adjunct Asst. Prof., Dpt. of Health, Behavior & Society 





Ahna Neustadt, BS 
Graduate Student,  
Genetic Counseling Training Program 








Appendix E: Script for Recruitment Phone Calls 
 
Hello. I am calling for (name of participant). Am I speaking with the correct person? 
Hi, my name is Ahna Neustadt. I am a graduate student from Johns Hopkins and I am conducting 
research for my master’s thesis. Your genetic counselor from (clinic name) has acquired 
permission from you that I may contact you for my research. I would like to tell you about my 
research project because you are eligible to participate. Are you interested in hearing about my 
study and what your participation would involve?  
If they say they are not interested: Okay that is fine. Thank you for your consideration! 
If they say they are interested: Great! I’m happy to hear you are interested in hearing more. My 
study is about how people who are seeking a diagnosis respond to genetic testing results from a 
test called exome sequencing. Your genetic counselor informed my research team that you 
received exome sequencing from (clinic name) as a way to try to get a diagnosis for a health 
condition.  We are curious to learn about your experience receiving your genetic test result and 
how this result has influenced how you think about your health. Your participation in the study 
would require a 45-60 minute phone interview and completing a short survey from home before 
the interview. After the interview you will be mailed a $20 gift card for your time.  Does this 
sound like something you would like to participate in?  
                   If they say no: Okay that is fine. Thank you for your consideration! 
If they say yes: Wonderful! I will go ahead and send you a consent form, which will 
explain more details about the project and what your participation would involve. 
Would you prefer I send this to you by mail or email? 
 
Please review the consent form and contact me at any time if you have questions 
about it or the research project. You will find my contact information at the end of 
the consent form. If you agree with the terms on the consent form and would like to 
participate in the phone interview, you will need to sign the consent form and send it 
back to me before your interview date. You can send it to me by mail, email, fax, 
whatever method is most preferable to you. Let’s go ahead and schedule a date now 
for your phone interview. 
What phone number would you like me to call for the phone interview? 
Also, along with the consent form, I will be sending you two short surveys to fill out. 
Please fill these out before your interview date. You do not need to return these back 
to me. Instead, hold on to them and on our interview date, I will collect your 
answers to these surveys verbally before we begin the interview.  
Do you have any further questions?  








Follow-Up Phone Call 
Hello. I am calling for (name of participant). Am I speaking with the correct person? 
Hi, my name is Ahna Neustadt. I am a graduate student from Johns Hopkins and I am conducting 
research for my master’s thesis. I am calling about the research project about genetic testing that 
you should have received a recruitment letter for. I was wondering if you received this 
recruitment letter?  
If they say they did not receive the recruitment letter: I see. Well I’d like to tell you a bit about 
this study that you are eligible to participate in if you have a moment? 
If they say they are not interested: Okay that is fine. Thank you for your consideration! 
If they say they are interested: Great! I’m happy to hear you are interested in hearing 
more. The study is about how people who are seeking a diagnosis respond to genetic 
testing results from a test called exome sequencing. Your genetic counselor informed my 
research team that you received exome sequencing from (clinic name) as a way to try to 
get a diagnosis for a health condition.  We are curious to learn about your experience 
receiving your genetic test result and how this result has influenced how you think about 
your health. Your participation in the study would require a 45-60 minute phone 
interview and completing a short survey from home before the interview. After the 
interview you will be mailed a $20 gift card for your time.  Does this sound like 
something you would like to participate in?  
 If they say no: Okay that is fine. Thank you for your consideration! 
If they say yes: Wonderful! I will go ahead and send you a consent form, 
which will explain more details about the project and what your 
participation would involve. Would you prefer I send this to you by mail 
or email? 
 
Please review the consent form and contact me at any time if you have 
questions about it or the research project. You will find my contact 
information at the end of the consent form. If you agree with the terms on 
the consent form and would like to participate in the phone interview, you 
will need to sign the consent form and send it back to me before your 
interview date. You can send it to me by mail, email, fax, whatever method 
is most preferable to you. Let’s go ahead and schedule a date now for 
your phone interview.  
What phone number would you like me to call for the phone interview? 
Also, along with the consent form, I will be sending you two short surveys 
to fill out. Please fill these out before your interview date. You do not need 
to return these back to me. Instead, hold on to them and on our interview 
date I will collect your answers to these surveys verbally before we begin 
the interview.  





I look forward to our phone interview on (date /time scheduled). Thank 
you! 
If they say they did receive the recruitment letter: Oh good I’m glad you received it. Since I 
haven’t heard back from you in a few weeks since I sent out the recruitment letter, I was 
wondering whether you are interested in hearing more or thinking about participating in the 
research project? 
If they say they are not interested: Okay that is fine. Thank you for your consideration! 
If they say they are interested: Great! I’m happy to hear you are interested in hearing 
more. The study is about how people who are seeking a diagnosis respond to genetic 
testing results from a test called exome sequencing. Your genetic counselor informed my 
research team that you received exome sequencing from (clinic name) as a way to try to 
get a diagnosis for a health condition.  We are curious to learn about your experience 
receiving your genetic test result and how this result has influenced how you think about 
your health. Your participation in the study would require a 45-60 minute phone 
interview and completing a short survey from home before the interview. After the 
interview you will be mailed a $20 gift card for your time. Does this sound like 
something you would like to participate in?  
 If they say no: Okay that is fine. Thank you for your consideration! 
If they say yes: Wonderful! I will go ahead and send you a consent form, 
which will explain more details about the project and what your 
participation would involve. Would you prefer I send this to you by mail 
or email? 
 
Please review the consent form and contact me at any time if you have 
questions about it or the research project. You will find my contact 
information at the end of the consent form. If you agree with the terms on 
the consent form and would like to participate in the phone interview, you 
will need to sign the consent form and send it back to me before your 
interview date. You can send it to me by mail, email, fax, whatever method 
is most preferable to you. Let’s go ahead and schedule a date now for 
your phone interview.  
What phone number would you like me to call for the phone interview? 
Also, along with the consent form, I will be sending you two short surveys 
to fill out. Please fill these out before your interview date. You do not need 
to return these back to me. Instead, hold on to them and on our interview 
date I will collect your answers to these surveys verbally before we begin 
the interview.  
Do you have any further questions?  







Appendix F: Consent Form - Kennedy Krieger Institute 
 
 
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
INFORMED CONSENT FOR ADULT PARTICIPANTS 
Study Title: Adult Patients with Undiagnosed Conditions and their Responses to Clinically 
Uncertain Results from Exome Sequencing 
 
Principal Investigator:  Jill Owczarzak 
IRB No.:  IRB00008725 
PI Version Date:  Version 3; 5/8/18 
What you should know about this study 
 You are being asked to join a research study.   
 This consent form explains the research study and your part in the study.   
 Please read it carefully and take as much time as you need.  
 You are a volunteer.  You may choose not to take part at all, and if you join, you may 
quit at any time.  There will be no penalty if you decide to quit the study.   
 During the study, we will tell you if we learn any new information that might affect 
whether you wish to continue to be in the study. 
 
 
Purpose of research project 
This research is being done to understand how people think, feel, and act after receiving their 
genetic test results. 
  
Why we are asking you to participate 
You are being asked to participate because you have had a genetic test called an exome sequence 
through Kennedy Krieger Institute.  We are interested in hearing from about 40 people who have 
received different kinds of results from the genetic test called exome sequencing. You can take 
part in this study if you were 18 years or older at the time you received your test result, and if you 
are English speaking. 
 
Study procedures 
You will be asked to take part in a 45-60 minute interview on the telephone, as well as fill out 2 
short surveys before the interview. We will audio record the interview, and it will later be 
transcribed. The interview will ask you some questions about what led up to the exome 
sequencing test and what your reactions were like when you got your test result. You will also be 









There are no physical risks of taking part in this study. However, it is possible that some 
questions may make you feel upset or anxious. If partaking in the interview makes you feel upset 
you can stop the interview at any point or skip any questions you do not wish to answer. If you 
feel upset after completing the interview or have any additional concerns, you may contact the 
researchers using the information provided below.  Talking about your test result may also raise 
some questions for you.  If that happens, we will refer you to someone who may be able to 
answer those questions. 
 
Benefits 
You are not expected to benefit directly from taking part in this study. The information you 
provide may help to improve our understanding of what it is like for individuals to get different 
kinds of genetic test results from exome sequencing. We hope that this will help genetic 
counselors improve how they talk about results with their patients.  We also hope that it will help 




You will receive a $20 gift card for participating in the study. If you choose to quit the study 
early, you will only receive the $20 gift card if you complete at least half of the interview.  
 
Data Sharing and Confidentiality 
Any personal information that you provide to us will be stored in a private and confidential 
manner. Your name and contact information will be linked with an ID number, and the ID 
number will be linked to information about you and your interview. The file that links your name 
to your ID number and contact information will be kept in a secure and password-controlled 
location. Everything will be labeled only with your ID number. Once we have finished your 
interview, we will delete the file with your name and contact information. Your responses will 
not be part of any medical record. When we report our research results, it will be done without 
identifiable information from individual people. If you mention any specific names during your 
interview, we will not transfer any of their personal information, including their names, into the 
transcript. 
 
Protecting your privacy during data collection 
Interviews will take place over the phone. To ensure your privacy, please make sure that the 
location you choose to be in during your phone interview is private enough. We recommend you 







What happens if you leave the study early?   
If partaking in the interview makes you feel upset you can stop the interview at any point or skip 
any questions you do not wish to answer. If you choose to stop the interview, you can decide 
whether or not you would like the parts of the interview you finished to be included in the study. 
 
Authorization for Disclosure of Protected Health Information for Research 
 
We are asking you to authorize the disclosure and use of your private health information for this 
research study.  By signing this authorization, you agree that Kennedy Krieger Institute may 
release your private health information to us for use in this research study. 
Your private health information that we may use for this research includes: 
 Category of result from exome sequencing (either variant of unknown significance or 
negative - but not information about the specific genetic change). 
 Number of days between the date you elected exome sequencing and the date you 
received your genetic test results. 
 Approximate date you received your exome sequencing result (only month and year). 
 Whether or not you have received a diagnosis since getting exome sequencing (yes or 
no). 
 Your personal description of your medical condition that you provide during your 
telephone interview. 
 
The people who may receive or use your private health information include the researchers and 
their staff. 
Kennedy Krieger Institute is required by the Federal Privacy Rule to protect your private health 
information.  By signing this Authorization, you permit them to release your information to the 
researchers for use in this research study.  The researchers will try to make sure that everyone 
who needs to see your private information for this research keeps it confidential, but we cannot 
guarantee this. Although the researchers may not be covered by the Federal Privacy Rule, they 
will make an effort to protect your information using the same standards.      
Some other people may see your private health information outside of the research team.  They 
may include the sponsor of the study, study safety monitors, government regulators, and legal 
compliance staff.   All these people must also keep your information confidential. 
You do not have to sign this Authorization, but otherwise you may not join the study.  It is your 
choice. 
Your Authorization does not have an expiration date; it will continue as long as the research 
continues.  You may change your mind and take back this Authorization at any time.  If you take 
it back, the researchers may still use the private health information they have collected about you 








Who do I call if I have questions or problems? 
 Call the senior investigator, Lori Erby, at 301-443-2635 if you have questions or 
complaints. You may also call the student investigator, Ahna Neustadt, at 301-827-5031. 
 
 Call or contact the Johns Hopkins Bloomberg School of Public Health IRB Office if 
you have questions about your rights as a participant. Contact the IRB if you feel you 
have not been treated fairly or if you have other concerns.  The IRB contact information 
is:   
 
Address: Johns Hopkins Bloomberg School of Public Health 
  615 N. Wolfe Street, Suite E1100, Baltimore, MD   21205 
 Telephone: 410-955-3193;     Toll Free: 1-888-262-3242 
        E-mail: jhsph.irboffice@jhu.edu 
 
What does your signature on this consent form mean? 
Your signature on this form means: 
 You have been informed about this study’s purpose, procedures, possible benefits and risks. 
 You have been given the chance to ask questions before you sign. 
 You have voluntarily agreed to be in this study.  
 
_____________________________   ___________________________________   __________ 
Print name of Adult Participant                 Signature of Adult Participant                                Date                                                           
 
_____________________________   ___________________________________   __________ 
Print name of Person Obtaining Consent  Signature of Person Obtaining Consent                   Date                                                          
 Please check the box ONLY if you prefer your phone interview to NOT be audio-recorded. If 
you check this box, we will make sure there is a note-taker present during your interview 
instead. 
Please send your signed consent form to the student investigator, Ahna Neustadt. You can 
return this in one of the following ways: 
 Email: ahna.neustadt@nih.gov 
 Mail:  Ahna Neustadt  
           31 Center Dr 
           B1B36 
           Bethesda, MD 20892 











Appendix G: Consent Form - Johns Hopkins Hospital Genetics Clinics 
 
 
JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH 
INFORMED CONSENT FOR ADULT PARTICIPANTS 
Study Title: Adult Patients with Undiagnosed Conditions and their Responses to Clinically 
Uncertain Results from Exome Sequencing 
 
Principal Investigator:  Jill Owczarzak 
IRB No.:  IRB00008725 
PI Version Date:  Version 3; 5/8/18 
What you should know about this study 
 You are being asked to join a research study.   
 This consent form explains the research study and your part in the study.   
 Please read it carefully and take as much time as you need.  
 You are a volunteer.  You may choose not to take part at all, and if you join, you may 
quit at any time.  There will be no penalty if you decide to quit the study.   
 During the study, we will tell you if we learn any new information that might affect 
whether you wish to continue to be in the study. 
 
Purpose of research project 
This research is being done to understand how people think, feel, and act after receiving their 
genetic test results. 
  
Why we are asking you to participate 
You are being asked to participate because you have had a genetic test called an exome sequence 
through Johns Hopkins Hospital Genetics Clinic.  We are interested in hearing from about 40 
people who have received different kinds of results from the genetic test called exome 
sequencing. You can take part in this study if you were 18 years or older at the time you received 
your test result, and if you are English speaking. 
 
Study procedures 
You will be asked to take part in a 45-60 minute interview on the telephone, as well as fill out 2 
short surveys before the interview. We will audio record the interview, and it will later be 
transcribed. The interview will ask you some questions about what led up to the exome 
sequencing test and what your reactions were like when you got your test result. You will also be 








There are no physical risks of taking part in this study. However, it is possible that some 
questions may make you feel upset or anxious. If partaking in the interview makes you feel upset 
you can stop the interview at any point or skip any questions you do not wish to answer. If you 
feel upset after completing the interview or have any additional concerns, you may contact the 
researchers using the information provided below.  Talking about your test result may also raise 
some questions for you.  If that happens, we will refer you to someone who may be able to 
answer those questions. 
 
Benefits 
You are not expected to benefit directly from taking part in this study. The information you 
provide may help to improve our understanding of what it is like for individuals to get different 
kinds of genetic test results from exome sequencing. We hope that this will help genetic 
counselors improve how they talk about results with their patients.  We also hope that it will help 




You will receive a $20 gift card for participating in the study. If you choose to quit the study 
early, you will only receive the $20 gift card if you complete at least half of the interview.  
 
Data Sharing and Confidentiality 
Any personal information that you provide to us will be stored in a private and confidential 
manner. Your name and contact information will be linked with an ID number, and the ID 
number will be linked to information about you and your interview. The file that links your name 
to your ID number and contact information will be kept in a secure and password-controlled 
location. Everything will be labeled only with your ID number. Once we have finished your 
interview, we will delete the file with your name and contact information. Your responses will 
not be part of any medical record. When we report our research results, it will be done without 
identifiable information from individual people. If you mention any specific names during your 
interview, we will not transfer any of their personal information, including their names, into the 
transcript. 
 
Protecting your privacy during data collection 
 
Interviews will take place over the phone. To ensure your privacy, please make sure that the 
location you choose to be in during your phone interview is private enough. We recommend you 








What happens if you leave the study early?   
If partaking in the interview makes you feel upset you can stop the interview at any point or skip 
any questions you do not wish to answer. If you choose to stop the interview, you can decide 
whether or not you would like the parts of the interview you finished to be included in the study. 
 
Authorization for Disclosure of Protected Health Information for Research 
 
We are asking you to authorize the disclosure and use of your private health information for this 
research study.  By signing this authorization, you agree that Johns Hopkins Hospital Genetics 
Clinic may release your private health information to us for use in this research study. 
Your private health information that we may use for this research includes: 
 Category of result from exome sequencing (either variant of unknown significance or 
negative - but not information about the specific genetic change). 
 Number of days between the date you elected exome sequencing and the date you 
received your genetic test results. 
 Approximate date you received your exome sequencing result (only month and year). 
 Whether or not you have received a diagnosis since getting exome sequencing (yes or 
no). 
 Your personal description of your medical condition that you provide during your 
telephone interview. 
 
The people who may receive or use your private health information include the researchers and 
their staff. 
Johns Hopkins Hospital Genetics Clinic is required by the Federal Privacy Rule to protect your 
private health information.  By signing this Authorization, you permit them to release your 
information to the researchers for use in this research study.  The researchers will try to make sure 
that everyone who needs to see your private information for this research keeps it confidential, 
but we cannot guarantee this. Although the researchers may not be covered by the Federal 
Privacy Rule, they will make an effort to protect your information using the same standards.      
Some other people may see your private health information outside of the research team.  They 
may include the sponsor of the study, study safety monitors, government regulators, and legal 
compliance staff.   All these people must also keep your information confidential. 
You do not have to sign this Authorization, but otherwise you may not join the study.  It is your 
choice. 
Your Authorization does not have an expiration date; it will continue as long as the research 
continues.  You may change your mind and take back this Authorization at any time.  If you take 
it back, the researchers may still use the private health information they have collected about you 








Who do I call if I have questions or problems? 
 Call the senior investigator, Lori Erby, at 301-443-2635 if you have questions or 
complaints. You may also call the student investigator, Ahna Neustadt, at 301-827-5031. 
 
 Call or contact the Johns Hopkins Bloomberg School of Public Health IRB Office if 
you have questions about your rights as a participant. Contact the IRB if you feel you 
have not been treated fairly or if you have other concerns.  The IRB contact information 
is:   
 
Address: Johns Hopkins Bloomberg School of Public Health 
  615 N. Wolfe Street, Suite E1100, Baltimore, MD   21205 
 Telephone: 410-955-3193;     Toll Free: 1-888-262-3242 
        E-mail: jhsph.irboffice@jhu.edu 
What does your signature on this consent form mean? 
Your signature on this form means: 
 You have been informed about this study’s purpose, procedures, possible benefits and risks. 
 You have been given the chance to ask questions before you sign. 
 You have voluntarily agreed to be in this study.  
 
_____________________________   ___________________________________   __________ 
Print name of Adult Participant                 Signature of Adult Participant                                 Date                                                           
 
_____________________________   ___________________________________   __________ 
Print name of Person Obtaining Consent  Signature of Person Obtaining Consent                   Date                                                          
 
 Please check the box ONLY if you prefer your phone interview to NOT be audio-recorded. 
If you check this box, we will make sure there is a note-taker present during your interview 
instead. 
Please send your signed consent form to the student investigator, Ahna Neustadt. You can 
return this in one of the following ways: 
 Email: ahna.neustadt@nih.gov 
 Mail:  Ahna Neustadt  
           31 Center Dr 
           B1B36 
           Bethesda, MD 20892 









Appendix H: Intolerance of Uncertainty Short Form Scale 
 
Below are questions that help researchers understand how much an individual tolerates 
uncertainty. Before your scheduled interview, please take time to answer these questions and 
record your answers on this sheet. Before the researcher begins to ask interview questions, she 
will have you verbally report your answers to these questions on the phone. Your answers will 
be recorded and anonymized.  
Please circle the number that best corresponds to how much you agree with each item. 
 















1. Unforeseen events upset me greatly. 
1 2 3 4 5 
2. It frustrates me not having all the 
information I need. 
1 2 3 4 5 
3. Uncertainty keeps me from living a 
full life. 
1 2 3 4 5 
4. One should always look ahead so as to 
avoid surprises. 
1 2 3 4 5 
5. A small unforeseen event can spoil 
everything, even with the best of 
planning. 
1 2 3 4 5 
6. When it’s time to act, uncertainty 
paralyses me. 
1 2 3 4 5 
7. When I am uncertain I can’t function 
very well. 
1 2 3 4 5 
8. I always want to know what the future 
has in store for me. 
1 2 3 4 5 
9. I can’t stand being taken by surprise. 
1 2 3 4 5 
10. The smallest doubt can stop me from 
acting. 
1 2 3 4 5 
11. I should be able to organize 
everything in advance. 
1 2 3 4 5 
12. I must get away from all uncertain 
situations. 













Appendix I: Perceptions of Uncertainties in Genome Sequencing Scale 
 
Below are questions that help researchers understand how an individual feels about exome 
sequencing. Before your scheduled interview, please take time to answer these questions and 
record your answers on this sheet. Before the researcher begins to ask interview questions, she 
will have you verbally report your answers to these questions on the phone. Your answers will 
be recorded and anonymized.  
Perceptions of Uncertainties in Genome Sequencing (PUGS) 
Rate how certain you feel about the following aspects of your sequence results: 
 Very 
Uncertain 
   Very 
Certain 
1. What my  test results may mean for my 
health 
1 2 3 4 5 
2. What future actions I will need to take 
based on my test results 
1 2 3 4 5 
3. Whether to discuss my  test results with 
my non-genetics physician 
1 2 3 4 5 
4. How my physician may use my results 
to improve my health 
1 2 3 4 5 
5. Whether I am worried or concerned 
about my  test results 
1 2 3 4 5 
6. Whether my  test results reveal 
something alarming 
1 2 3 4 5 
7. Whether I am reassured or encouraged 
by my test results 
1 2 3 4 5 
8. Whether my  test results may disrupt 
my life 
1 2 3 4 5 
9. Whether I am able to trust my  test 
results 
1 2 3 4 5 
















Appendix J: Interview Guide 
Are you in a place that you feel is private enough to have this interview? 
Now that we have finished the informed consent process, I would like to ask you a few questions 
to collect demographic information about you: 
 
1) Would you describe your ethnicity as: 
         Hispanic or Latino 
         Not Hispanic or Latino 
 
2)  Which one or more categories describes your race? 
        American Indian or Alaska Native 
        Asian 
        Black or African American 
        Native Hawaiian or Other Pacific Islander 
         White 
        Other: _______________________ 
 
2) What level of education have you currently completed? 
       Graduate School  
       College Graduate  
       Some College  
       High School  
       Some High School or less 
 
3) What is your estimated annual household income? 
       <$45,000  
       $45,000–$89,999  
       ≥ $90,000 
 
4) How long have you been seeking a diagnosis for your condition? 
        6 months-1 year 
        1-2 years 
        2-3 years 
        3-4 years 
        5-10 years 
        over 10 years 
 
Thank you! Now I need to quickly collect your responses to the 2 short surveys I sent you. Do you 
have these answers ready to read aloud to me?  
Response 1: Great! I’ll go over each question and you tell me the number that you 
selected for your answer. 
Response 2: Oh, you haven’t completed the surveys yet. Alright, well let’s complete it 
together now then. I’ll go over each question and you can tell me the number you select 





Now we’ll begin the interview. As a reminder, it’s ok to mention any provider, family or friend’s 
name as they will not be transcribed for the study. During our conversation, I would like you to 
focus on the experience of receiving your genetic test result and how this result has affected you. 
Although we’ll primarily talk about your testing experience, first tell me a bit about your 
experience with trying to find a diagnosis before you had the exome sequencing test. (Prompt if 
necessary: Focus on aspects of uncertainty related to this experience.) 
 PROMPT: Before getting exome sequencing, did you have any ideas about what was 
causing your symptoms/condition? If so, what were your ideas about this? 
 Can you briefly describe your symptoms?  
Thank you. Now, let’s talk about what led to you to decide to seek genetic testing for your 
undiagnosed condition.  
 What led you to get exome sequencing at (insert clinic name)? 
o PROMPT: 
 Had you heard about exome sequencing before your visit at (insert clinic 
name)? If so, what did you already know about exome sequencing? 
Where did you learn this information?  
 Did your prior knowledge influence your decision to pursue exome 
sequencing? In what ways? 
 What were reasons you might have wanted exome sequencing? 
 Were there any reasons why you were unsure? 
Now I’d like to ask you about your test result and your experiences on the day you received your 
test result. 
 Who told you about your result? 
 Was it in person or over the phone? 
 Was there anyone else with you when you learned about your result? If so, who were 
they?  
 
 What did the (insert response about who told the results) say to you about your exome 
sequencing result? 
o PROMPTS: 
 Do you remember what they called the type of result? 
 What did they say about it being or not being the cause of your 
symptoms/condition? 
 Did they say the result would have any medical consequences for your 
family members? 
 
 Did the information the (insert response about who told the results) tell you make sense 
at the time you were first hearing it? 
o PROMPTS:  
 What made sense and what did not make sense? 






 Did the information the (insert response about who told the results) tell you meet your 
hopes and expectations? 
o PROMPTS:  
 What did you expect to learn from exome sequencing? 
 Did you expect to get a diagnosis? 
 What different kinds of results did you understand were possible 
to get from exome sequencing? 
 What were you hoping the results would be?  
 How confident were you that exome sequencing would provide a 
diagnosis? 
 How did exome sequencing compare to other genetic tests you had 
previously? 
 
 Did you seek additional information after your meeting with (insert response about who 
told the results)? If so, what additional information were you looking for? What did you 
do to learn more?  
Now I’d like to ask you about how you reacted after receiving this test result.  
 What thoughts ran through your mind when you first learned about your result? 
o PROMPTS: 
 Did the result make you think differently about the cause of your 
symptoms/condition? If so, in what ways? 
 Did you react the way you expected to? 
 How would you describe your emotions in that moment? 
 
 Have you told anyone about your result? If so, who did you talk to? 
o PROMPTS: Healthcare providers? Family members? Friends? 
 What did you tell them? 
o PROMPTS:  
 Why did you choose to tell the people you did? 
 Was there anyone that you specifically chose not to tell? If so, why did 
you choose not to tell them? 
 
 Has receiving your exome results influenced you to take any actions? 
o PROMPTS: 
 Have you sought additional testing/second opinion? If so, why? Did you 
learn anything new or different? 
 Have you sought additional or new medical care? If yes, please explain 
the types of care you have sought and why. If no, explain why you have 
not sought new care. 
 Have you chosen to participate in any research related to your result or 
your symptoms/condition? If yes, please explain the type of research you 





 Have you joined any support groups? If yes, please explain the type(s) of 
support group(s) you have joined and why.  
 Have you participated in advocacy activities related to your result or 
your symptoms/condition? If yes, please explain the types of advocacy 
activities you have participated in and why. 
 
 Does the way you feel about your exome sequencing result today differ from the way you 
felt about it after first hearing about it? If so, how are your feelings different? 
o PROMPTS: 
 Have your thoughts about your result in relation to your 
symptoms/condition changed overtime? 
 What has contributed to you feeling differently? 
 
 Overall, how do you think you have dealt with knowing your result? What do you do to 
cope? 
o PROMPTS: 
 (if they have described their result as uncertain): How do you cope with 
the uncertainty of your result? 
 What has been most difficult for you about receiving your result? What has been most 
helpful? 
 
 At this current time (if still undiagnosed): 
o Is there still additional information you feel like you need to help you make sense 
of your result? 
o Do you expect to hear from someone again about your genetic test result? If so, 
when and why? 
o If new information became available about your result would you want to learn 
about it? Why?  
o At this current time (if since been diagnosed): 
o What tests have you had after exome sequencing that have given you further 
information about your symptoms/conditions (provided you with a diagnosis)? 
We’ve come to the end of the interview. I want to thank you again for agreeing to participate. 
Before we wrap up, are there any questions you have for me? Is there anything you were 
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